Characteristics of relapsed case subjects and successfully treated matched control subjects with acute lymphoblastic leukemia selected from trials ALL-BFM 86 and ALL-BFM 90
| . | No. of Subjects and Prevalence (%) . | |
|---|---|---|
| Cases (n = 64) . | Controls (n = 64) . | |
| Trial | ||
| ALL-BFM 86 | 35 (54.7) | 35 (54.7) |
| ALL-BFM 90 | 29 (45.3) | 29 (45.3) |
| Sex | ||
| Male | 42 (65.6) | 42 (65.6) |
| Female | 22 (34.4) | 22 (34.4) |
| Age (y) | ||
| <1 | 1 (1.6) | 1 (1.6) |
| 1-9 | 56 (87.5) | 56 (87.5) |
| 10-14 | 6 (9.4) | 7 (10.9) |
| 15-18 | 1 (1.6) | — |
| WBC* (103/μL) | ||
| <10 | 42 (65.6) | 41 (64.1) |
| 10-<50 | 21 (32.8) | 22 (34.4) |
| ≥50 | 1 (1.6) | 1 (1.6) |
| Immunophenotype | ||
| c-ALL† | 54 (84.4) | 54 (84.4) |
| Pre-B-ALL‡ | 10 (15.6) | 10 (15.6) |
| Risk group1-153 | ||
| Standard | 23 (35.9) | 23 (35.9) |
| Intermediate | 41 (64.1) | 41 (64.1) |
| High | — | — |
| DNA index1-155 | ||
| <1.16 | 30 (46.9) | 30 (46.9) |
| ≥1.16 | 12 (18.8) | 7 (10.9) |
| Not examined | 22 (34.4) | 27 (42.2) |
| Genotype | ||
| Normal | 4 (6.3) | 10 (15.6) |
| 11q23 Aberrations | — | 1 (1.6) |
| t(1;19) | 1 (1.6) | — |
| t(9;22) | — | — |
| Other | 15 (23.3) | 13 (20.3) |
| Not examined | 44 (68.8) | 40 (62.5) |
| . | No. of Subjects and Prevalence (%) . | |
|---|---|---|
| Cases (n = 64) . | Controls (n = 64) . | |
| Trial | ||
| ALL-BFM 86 | 35 (54.7) | 35 (54.7) |
| ALL-BFM 90 | 29 (45.3) | 29 (45.3) |
| Sex | ||
| Male | 42 (65.6) | 42 (65.6) |
| Female | 22 (34.4) | 22 (34.4) |
| Age (y) | ||
| <1 | 1 (1.6) | 1 (1.6) |
| 1-9 | 56 (87.5) | 56 (87.5) |
| 10-14 | 6 (9.4) | 7 (10.9) |
| 15-18 | 1 (1.6) | — |
| WBC* (103/μL) | ||
| <10 | 42 (65.6) | 41 (64.1) |
| 10-<50 | 21 (32.8) | 22 (34.4) |
| ≥50 | 1 (1.6) | 1 (1.6) |
| Immunophenotype | ||
| c-ALL† | 54 (84.4) | 54 (84.4) |
| Pre-B-ALL‡ | 10 (15.6) | 10 (15.6) |
| Risk group1-153 | ||
| Standard | 23 (35.9) | 23 (35.9) |
| Intermediate | 41 (64.1) | 41 (64.1) |
| High | — | — |
| DNA index1-155 | ||
| <1.16 | 30 (46.9) | 30 (46.9) |
| ≥1.16 | 12 (18.8) | 7 (10.9) |
| Not examined | 22 (34.4) | 27 (42.2) |
| Genotype | ||
| Normal | 4 (6.3) | 10 (15.6) |
| 11q23 Aberrations | — | 1 (1.6) |
| t(1;19) | 1 (1.6) | — |
| t(9;22) | — | — |
| Other | 15 (23.3) | 13 (20.3) |
| Not examined | 44 (68.8) | 40 (62.5) |
WBC: White blood cell count.
Common acute lymphoblastic leukemia; see “Results” or definition.
Pre-B-cell acute lymphoblastic leukemia; see “Results” for definition.
Therapy stratification in risk groups is mainly based on initial leukemic cell mass estimate and initial treatment response; see “Materials and Methods” for exact definition.
Ratio of DNA content of leukemic G0/G1cells-to-normal diploid lymphocytes.